- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Ryvu Therapeutics SA (RVU)
Ryvu Therapeutics SA stock price live, this page displays WA RVU stock exchange data. View the RVU premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Ryvu Therapeutics SA real time stock price chart below.
What Is the Ryvu Therapeutics SA Stock Price Today?
The Ryvu Therapeutics SA stock price today is 14.20.
What Is the Stock Symbol for Ryvu Therapeutics SA?
The stock symbol for Ryvu Therapeutics SA is "RVU."
What Stock Exchange Does Ryvu Therapeutics SA Trade On?
Ryvu Therapeutics SA is listed and trades on the Warsaw stock exchange.
Is Ryvu Therapeutics SA a Good Stock to Buy?
Determining whether Ryvu Therapeutics SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RVU quote. (ISIN: PLSELVT00013)
What Is the Ryvu Therapeutics SA Stock Price Today?
The Ryvu Therapeutics SA stock price today is 14.20.
What Is the Stock Symbol for Ryvu Therapeutics SA?
The stock symbol for Ryvu Therapeutics SA is "RVU."
What Stock Exchange Does Ryvu Therapeutics SA Trade On?
Ryvu Therapeutics SA is listed and trades on the Warsaw stock exchange.
Is Ryvu Therapeutics SA a Good Stock to Buy?
Determining whether Ryvu Therapeutics SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RVU quote. (ISIN: PLSELVT00013)
14.20
-0.10(-0.70%)
Delayed Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.20
14.30
52 wk Range
13.64
32.50
RVU is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.2014.30
52 wk Range
13.6432.50
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
RVU Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
33.62
Upside
+136.76%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell
Analyst Ratings
2 Buy
3 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 33.62
(+136.76% Upside)
Earnings
Latest Release
May 20, 2026
EPS / Forecast
-0.55 / --
Revenue / Forecast
21.7M / --
Compare RVU to Peers and Sector
Metrics to compare | RVU | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRVUPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.7x | −8.9x | −0.4x | |
PEG Ratio | −0.12 | 0.01 | 0.00 | |
Price/Book | 8.0x | 2.0x | 2.6x | |
Price / LTM Sales | 3.7x | 3.6x | 3.0x | |
Upside (Analyst Target) | 102.8% | 35.7% | 58.1% | |
Fair Value Upside | Unlock | 15.0% | 8.2% | Unlock |
Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company’s lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It also develops Dapolsertib (SEL24/MEN1703), a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up for Phase 2 clinical trial for the treatment of diffuse large b-cell lymphoma and acute myeloid leukemia. In addition, the company’s early pipeline candidates include candidates in the areas of kinases, synthetic lethality, immunometabolism, and immuno-oncology. It has collaborations with BioNTech SE to advance small molecule programs to target immune modulation in cancer and other disease areas; Exelixis Inc. for the development of targeted therapies based on Ryvu’s STING agonist technology. The company was formerly known as Selvita S.A. and changed its name to Ryvu Therapeutics S.A. in October 2019. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Ryvu (RVU) Stock Price Today?
The Ryvu stock price today is 14.20 PLN.
What Stock Exchange Does Ryvu Trade On?
Ryvu is listed and trades on the Warsaw Stock Exchange.
What Is the Stock Symbol for Ryvu?
The stock symbol for Ryvu is "RVU."
What Is the Ryvu Market Cap?
As of today, Ryvu market cap is 330.62M PLN.
What Is Ryvu's Earnings Per Share (TTM)?
The Ryvu EPS (TTM) is -3.84.
When Is the Next Ryvu Earnings Date?
Ryvu will release its next earnings report on Sep 10, 2026.
From a Technical Analysis Perspective, Is RVU a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Ryvu Stock Split?
Ryvu has split 0 times.
How Many Employees Does Ryvu Have?
Ryvu has 228 employees.
What is the current trading status of Ryvu (RVU)?
As of Jun 22, 2026, Ryvu (RVU) is trading at a price of 14.20 PLN, with a previous close of 14.30 PLN. The stock has fluctuated within a day range of 14.20 PLN to 14.30 PLN, while its 52-week range spans from 13.64 PLN to 32.50 PLN.
What Is Ryvu (RVU) Price Target According to Analysts?
The average 12-month price target for Ryvu is 33.62 PLN, with a high estimate of 49.1 PLN and a low estimate of 17 PLN. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +136.76% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.